NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Yes—FDA is an important consideration. Thank you for again bringing more awareness to the years-long significant and meaningful connections among FDA—NIH—NCI—Dr. Liau—DCVax. I believe you are correct to imply that everyone should research these connections for themselves as they are becoming increasingly interesting connections while we await the peer review and regulatory process. It is always wise to verify facts and conduct your own independent research. Disinformation on social media abounds.

https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter

https://www.bentley.edu/news/nih-funded-research-related-every-new-cancer-drug-approved-2010-2016

https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/

https://connect.uclahealth.org/2022/09/14/brain-cancer-discovery-clinical-trials/

https://newsroom.ucla.edu/releases/nih-grant-lab-gene-cell-therapies

September 2022–
In a trial now underway, a dendritic cell vaccine is made from a participant’s own tumor tissue and combined with an anti-PD1 immune checkpoint inhibitor to counter resistance when either treatment is used alone. The checkpoint drugs work by blocking the proteins that stop the immune system from attacking cancer cells.

“What I’m excited about is that we’re seeing a growing number of long-term survivors in our patients treated with immunotherapy combinations,” Dr. Liau says. “We’re seeing some patients with certain combination immunotherapies that are living for many more years than would be expected. Currently, we’re trying to find out what combination works best and for which patients.”

March 2021–
Supported by the NIH’s Brain Initiative and the National Cancer Institute’s Specialized Program of Research Excellence (SPORE) grant, Dr. Liau is collaborating with research faculty in neuroscience, oncology and immunology to develop those brain cancer vaccines and other novel treatments for brain diseases. Engaging in research also makes her more effective bedside, she says.

“It's the stamp of approval from the NIH, because these types of grants are so rigorously peer-reviewed,” Dr. Liau says. “People get funded based on the strength of the science and that, itself, is very powerful in terms of showing that our research is scientifically valid and meaningful…”

November 2022–
Dr. Liau will be presenting DCVax at the annual Society for Neuro-Oncology meeting in November.

“The Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education.”

“The annual SNO meeting is the academic and educational nexus for the latest findings from all neuro-oncology subspecialties and disciplines.”

Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial

Plenary Abstract Presenter: Linda M. M. Liau, MD PhD
- University of California, Los Angeles

https://www.uclahealth.org/providers/linda-liau

https://soc-neuro-onc.org/

https://virtualtrials.org/dcvax.cfm